Therefore, we speculate that the poor prognosis of patients with AML harboring RUNX1, TP53, or ASXL1 mutations may be partly caused by the specific influences of these mutations on the leukemia-associated immune system. The gene discussed is RUNX1; the disease is acute myeloid leukemia.